MetaCap

Candel Therapeutics (CADL) vs Tevogen (TVGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Candel Therapeutics (CADL) has outperformed Tevogen (TVGN) over the past year, gaining 10.8% versus a loss of 73.8%. Tevogen is the larger company by market cap ($405.2 million vs $395.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CADL+10.77%TVGN-73.84%
+216%+60%-97%
Nov 21, 20251 yearNov 20, 2026
CADL-25.33%TVGN-98.81%
+104%-2%-109%
Jan 3, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CADL versus TVGN key metrics
MetricCADLTVGN
Share price$5.04$5.90
Market cap$395.37M$405.20M
1-day change-1.75%-6.35%
YTD return-10.80%-64.35%
1-year return+10.77%-73.84%
5-year return-48.47%—
EPS (TTM)$-1.53$-7.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-38.18M$-26.28M
52-week high$14.00$24.90
52-week low$4.35$3.64
Distance from 52-week high-64.00%-76.31%
Analyst consensusstrong_buy—
Avg. price target upside+250.60%—
Average volume1.26M7.94K
Shares outstanding78.45M68.68M
Employees5518
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CADL has outperformed TVGN by 84.6 percentage points over the past year.

About Candel Therapeutics

CADL stock →

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 55 employees

About Tevogen

TVGN stock →

Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees

CADL vs TVGN FAQ

Which is bigger, Candel Therapeutics or Tevogen?

Tevogen (TVGN) is larger, with a market capitalization of $405.20M compared with $395.37M for Candel Therapeutics (CADL).

Which stock has performed better over the past year, CADL or TVGN?

CADL returned +10.77% over the past 12 months, compared with -73.84% for TVGN (price return, excluding dividends). Past performance does not predict future results.

Are Candel Therapeutics and Tevogen in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons